MEDINCELL SA (MEDCL.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:MEDCL - FR0004065605 - Common Stock
26 EUR
+0.1 (+0.39%)
Overall MEDCL gets a fundamental rating of 4 out of 10. We evaluated MEDCL against 54 industry peers in the Pharmaceuticals industry. The financial health of MEDCL is average, but there are quite some concerns on its profitability. MEDCL is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year MEDCL has reported negative net income.
MEDCL had a positive operating cash flow in the past year.
In the past 5 years MEDCL always reported negative net income.
In the past 5 years MEDCL reported 4 times negative operating cash flow.
1.2 Ratios
MEDCL's Return On Assets of -20.38% is on the low side compared to the rest of the industry. MEDCL is outperformed by 78.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.38% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 95.46%, MEDCL belongs to the best of the industry, outperforming 96.36% of the companies in the same industry.
MEDCL's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for MEDCL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
2. Health
2.1 Basic Checks
MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MEDCL has been increased compared to 1 year ago.
The number of shares outstanding for MEDCL has been increased compared to 5 years ago.
The debt/assets ratio for MEDCL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.05 indicates that MEDCL is not in any danger for bankruptcy at the moment.
MEDCL has a Altman-Z score (4.05) which is comparable to the rest of the industry.
The Debt to FCF ratio of MEDCL is 3.30, which is a good value as it means it would take MEDCL, 3.30 years of fcf income to pay off all of its debts.
MEDCL has a Debt to FCF ratio of 3.30. This is comparable to the rest of the industry: MEDCL outperforms 58.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.3 | ||
| Altman-Z | 4.05 |
ROIC/WACCN/A
WACC7.7%
2.3 Liquidity
MEDCL has a Current Ratio of 2.70. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.70, MEDCL belongs to the best of the industry, outperforming 87.27% of the companies in the same industry.
MEDCL has a Quick Ratio of 2.70. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.70, MEDCL belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 |
3. Growth
3.1 Past
MEDCL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.16%, which is quite impressive.
Looking at the last year, MEDCL shows a very strong growth in Revenue. The Revenue has grown by 181.43%.
Measured over the past years, MEDCL shows a very strong growth in Revenue. The Revenue has been growing by 54.88% on average per year.
EPS 1Y (TTM)28.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.59%
Revenue 1Y (TTM)181.43%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%720.66%
3.2 Future
The Earnings Per Share is expected to grow by 50.22% on average over the next years. This is a very strong growth
Based on estimates for the next years, MEDCL will show a very strong growth in Revenue. The Revenue will grow by 40.22% on average per year.
EPS Next Y67.49%
EPS Next 2Y75.45%
EPS Next 3Y61.82%
EPS Next 5Y50.22%
Revenue Next Year11.6%
Revenue Next 2Y56.13%
Revenue Next 3Y69.91%
Revenue Next 5Y40.22%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
MEDCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MEDCL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
MEDCL's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. MEDCL is more expensive than 61.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 48.38 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MEDCL's earnings are expected to grow with 61.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.45%
EPS Next 3Y61.82%
5. Dividend
5.1 Amount
No dividends for MEDCL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:MEDCL (12/5/2025, 7:00:00 PM)
26
+0.1 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners30.76%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap861.38M
Revenue(TTM)25.42M
Net Income(TTM)-18.44M
Analysts84.71
Price Target35.36 (36%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.27%
PT rev (3m)48.86%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-54.4%
EPS NY rev (3m)-78.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-8.71%
Revenue NY rev (3m)-14.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 33.89 | ||
| P/FCF | 48.38 | ||
| P/OCF | 44.25 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)0.54
FCFY2.07%
OCF(TTM)0.59
OCFY2.26%
SpS0.77
BVpS-0.49
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.38% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.46% | ||
| FCFM | 70.05% |
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
F-Score7
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.3 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 83.42% | ||
| Cap/Sales | 6.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.7 | ||
| Altman-Z | 4.05 |
F-Score7
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)71.46%
Cap/Depr(5y)81.14%
Cap/Sales(3y)10.03%
Cap/Sales(5y)17.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.59%
EPS Next Y67.49%
EPS Next 2Y75.45%
EPS Next 3Y61.82%
EPS Next 5Y50.22%
Revenue 1Y (TTM)181.43%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%720.66%
Revenue Next Year11.6%
Revenue Next 2Y56.13%
Revenue Next 3Y69.91%
Revenue Next 5Y40.22%
EBIT growth 1Y48.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year91.35%
EBIT Next 3Y101.34%
EBIT Next 5Y84.97%
FCF growth 1Y235.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y263.28%
OCF growth 3YN/A
OCF growth 5YN/A
MEDINCELL SA / MEDCL.PA FAQ
What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA.
What is the valuation status of MEDINCELL SA (MEDCL.PA) stock?
ChartMill assigns a valuation rating of 1 / 10 to MEDINCELL SA (MEDCL.PA). This can be considered as Overvalued.
What is the profitability of MEDCL stock?
MEDINCELL SA (MEDCL.PA) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for MEDCL stock?
The Earnings per Share (EPS) of MEDINCELL SA (MEDCL.PA) is expected to grow by 67.49% in the next year.